The Middle EAST Malignant Lymphoma Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including an increasing incidence of malignant lymphoma, advancements in treatment options, and heightened awareness regarding early diagnosis. The region has witnessed a rise in...